Table 1.

Demographic data of training and validation cohorts

	RR-MSa	SP-MSb	PP-MSc
Training (n = 205)
n	86	42	77
Females/Males	54/32	21/21	39/38
Age, years	43.99 (18.01–76.43)	54.28 (31.24–73.82)e	57.94 (27.61–74.66)e
Disease Duration, years	13.91 (4–44)	26.52 (9–49)e	17.38 (6–45)d,f
MS-DSS	1.44 (0.56–3.42)	2.43 (0.87–5.19)e	2.30 (0.34–4.90)e
MSSS	2.83 (0.16–9.57)	6.21 (1.43–9.82)e	6.64 (0.64–9.85)e
Validation (n = 94)
n	47	28	19
Females/Males	30/17	10/18	11/8
Age, years	43.39 (24.95–65.44)	53.44 (22.02–68.04)d	59.19 (34.90–69.68)e
Disease Duration, years	14.51 (3–33)	23.32 (8–33)d	19.39 (8–46)e
MS-DSS	1.61 (0.51–2.31)	2.49 (0.81–5.33)d	2.22 (0.81–4.43)d
MSSS	2.98 (0.26–8.75)	6.98 (1.7–9.56)e	6.71 (2.55–9.56)e

Continuous data are shown as the mean of all measurements and the minimum and maximum values are in parentheses.

^aRelapsing-remitting MS

^bSecondary progressive MS

^cPrimary progressive MS

^dp < 0.05 when compared to RR-MS using one-way ANOVA with Holm adjustment for multiple comparisons

^ep < 0.0001 when compared to RR-MS using one-way ANOVA with Holm adjustment for multiple comparisons

^fp < 0.0001 when compared to SP-MS using one-way ANOVA with Holm adjustment for multiple comparisons